Genolution Inc. - Asset Resilience Ratio

Latest as of September 2025: 3.80%

Genolution Inc. (225220) has an Asset Resilience Ratio of 3.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 225220 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩3.79 Billion
≈ $2.57 Million USD Cash + Short-term Investments

Total Assets

₩99.84 Billion
≈ $67.66 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Genolution Inc.'s Asset Resilience Ratio has changed over time. See 225220 net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Genolution Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genolution Inc. market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩3.79 Billion 3.8%
Total Liquid Assets ₩3.79 Billion 3.80%

Asset Resilience Insights

  • Limited Liquidity: Genolution Inc. maintains only 3.80% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Genolution Inc. Industry Peers by Asset Resilience Ratio

Compare Genolution Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.10%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 4.52%
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 35.56%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Genolution Inc. (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Genolution Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 31.20% ₩33.21 Billion
≈ $22.51 Million
₩106.45 Billion
≈ $72.14 Million
-6.49pp
2023-12-31 37.69% ₩42.75 Billion
≈ $28.97 Million
₩113.44 Billion
≈ $76.88 Million
-2.82pp
2022-12-31 40.51% ₩46.37 Billion
≈ $31.42 Million
₩114.45 Billion
≈ $77.56 Million
-7.87pp
2021-12-31 48.38% ₩45.93 Billion
≈ $31.13 Million
₩94.94 Billion
≈ $64.34 Million
-10.06pp
2020-12-31 58.44% ₩48.96 Billion
≈ $33.18 Million
₩83.77 Billion
≈ $56.77 Million
+30.02pp
2019-12-31 28.42% ₩3.82 Billion
≈ $2.59 Million
₩13.43 Billion
≈ $9.10 Million
-18.57pp
2018-12-31 46.99% ₩5.21 Billion
≈ $3.53 Million
₩11.10 Billion
≈ $7.52 Million
+1.21pp
2017-12-31 45.78% ₩2.15 Billion
≈ $1.46 Million
₩4.71 Billion
≈ $3.19 Million
-12.50pp
2016-12-31 58.28% ₩2.33 Billion
≈ $1.58 Million
₩3.99 Billion
≈ $2.71 Million
--
pp = percentage points

About Genolution Inc.

KQ:225220 Korea Biotechnology
Market Cap
$22.90 Million
₩33.78 Billion KRW
Market Cap Rank
#24585 Global
#1815 in Korea
Share Price
₩1870.00
Change (1 day)
-0.95%
52-Week Range
₩1616.00 - ₩2645.00
All Time High
₩10300.23
About

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more